New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
10:52 EDTICPTIntercept intends to file for accelerated approval in PBC
Intercept said in conference presentation slides that it intends to file for accelerated approval for OCA in primary biliary cirrhosis, or PBC, conditional on conducting an additional Phase 3 confirmatory clinical outcomes trial for full approval.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
07:52 EDTICPTIntercept volatility elevated as shares trend higher
Intercept overall option implied volatility of 71 compares to its 26-week average of 66 according to Track Data, suggesting large price movement.
March 4, 2015
16:34 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
Subscribe for More Information
15:52 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
11:09 EDTICPTSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
March 3, 2015
07:35 EDTICPTIntercept risk/reward positive, says RBC Capital
RBC Capital believes that Intercept will rally 20% or more if GenFit data, expected to be announced in the second half of March, isn't clean. If the GenFit data is positive, Intercept's stock might drop, but it would probably rebound, since the company would probably reach a deal with the FDA on a Phase III trial of its OCA drug soon thereafter, according to the firm. RBC keeps a $490 price target and Outperform rating on Intercept.
March 2, 2015
06:13 EDTICPTIntercept reports Q4 EPS ($1.63), consensus ($1.67)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use